HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Alnylam Pharmaceuticals, maintaining a price target of $400.
August 30, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Alnylam Pharmaceuticals, maintaining a price target of $400, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a high price target of $400 by HC Wainwright & Co. suggests strong confidence in Alnylam Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100